KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$26.5 million.

  • Novavax's Change in Accured Expenses fell 21375.72% to -$26.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$343.5 million, marking a year-over-year increase of 783.76%. This contributed to the annual value of -$385.6 million for FY2024, which is 180.07% down from last year.
  • Latest data reveals that Novavax reported Change in Accured Expenses of -$26.5 million as of Q3 2025, which was down 21375.72% from -$62.6 million recorded in Q2 2025.
  • Novavax's 5-year Change in Accured Expenses high stood at $823.0 million for Q4 2022, and its period low was -$272.5 million during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is $23.6 million, with a median of -$29.5 million in 2023.
  • In the last 5 years, Novavax's Change in Accured Expenses soared by 73106.51% in 2021 and then crashed by 31659.63% in 2022.
  • Quarter analysis of 5 years shows Novavax's Change in Accured Expenses stood at $419.6 million in 2021, then skyrocketed by 96.13% to $823.0 million in 2022, then plummeted by 103.59% to -$29.5 million in 2023, then tumbled by 43.74% to -$42.5 million in 2024, then skyrocketed by 37.52% to -$26.5 million in 2025.
  • Its last three reported values are -$26.5 million in Q3 2025, -$62.6 million for Q2 2025, and -$211.8 million during Q1 2025.